purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation tmo earnings call period ending december image source motley fool thermo fisher scientific tmo q earnings calljan etcontents prepared remark question answer call participant prepared remark operatorgood morning lady gentleman welcome thermo fisher scientific fourthquarter conference call name bailey moderator today call operator instruction would like introduce moderator call mr rafael tejada vice president investor relation mr tejada may begin callrafael tejada vice president investor relation good morning thank joining u call today marc casper chairman president chief executive officer stephen williamson senior vice president chief financial officer please note call webcast live archived investor section website thermofishercom heading news event presentation february th copy press release fourthquarter fullyear earnings available investor section website heading financials begin let briefly cover safe harbor statement various remark may make company future expectation plan prospect constitute forwardlooking statement purpose safe harbor provision private security litigation reform act actual result may differ materially indicated forwardlooking statement result various important factor including discussed company recent annual report form k subsequent quarterly report form q file sec available investor section website heading financials sec filing may elect update forwardlooking statement point future specifically disclaim obligation even estimate changeshould invest thermo fisher scientific right buy stock thermo fisher scientific consider motley fool stock advisor analyst team identified believe best stock investor buy thermo fisher scientific one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january therefore rely forwardlooking statement representing view date subsequent today also call referring certain financial measure prepared accordance generally accepted accounting principle gaap reconciliation nongaap financial measure directly comparable gaap measure available press release fourth quarter earnings also available investor section website heading financials turn call marc marc casper chairman president chief executive officer thank raf good morning everyone thanks joining u today fourthquarter call saw press release fourth quarter result ahead guidance provided call october demonstrates strong execution reflect performance full year proud team operated speed scale enable success customer demonstrating incredibly strong operational discipline commercial execution delivered differentiated shortterm performance time strengthening longterm competitive position get detail remark later first let recap financials starting quarter revenue billion adjusted operating income billion expanded adjusted operating margin basis point delivered another quarter strong adjusted eps performance growing adjusted eps per share term fullyear result revenue billion adjusted operating income billion adjusted eps per share last year delivered meaningful share gain industryleading product service expertise leveraged ppi business system enable outstanding execution including aggressively addressing cost base effectively navigate challenging macroeconomic environment time strengthened longterm competitive position highimpact innovation exciting complementary acquisition additional investment capability strengthening trusted partner status customer turning performance end market fourth quarter underlying market condition largely played line expectation continued strong execution resulted revenue performance slightly ahead expectation let provide color performance context end market starting pharma biotech expected growth declined high single digit quarter approximately full year vaccine therapy runoff resulted sevenpoint headwind customer segment effectively offset share gain result trusted partner status made strong progress transitioning covidrelated capacity therapy exciting future academic government grew midsingle digit quarter highsingle digit full year delivered strong growth across range business including electron microscopy chromatography mass spectrometry well research safety market channel industrial applied grew low single digit quarter full year year delivered strong growth electron microscopy business finally diagnostics healthcare q revenue declined high teen lower full year delivered good core business growth end market highlighted immunodiagnostics microbiology transplant diagnostic business turn update growth strategy reminder strategy consists three pillar high impact innovation trusted partner status customer unparalleled commercial engine starting first pillar another terrific year highimpact innovation throughout year launched outstanding new product across business strengthened industry leadership enabling customer advance important work chromatography mass spectrometry year highlighted launch groundbreaking thermo scientific orbitrap astral mass spectrometer helping customer uncover protein previously undetectable scientific breakthrough enabling customer advance precision medicine including identification new clinical biomarkers six month since launch scientific community adoption product exceeded high expectation momentum continuing build enter electron microscopy launched thermo scientific metrios stem fully automated system enables customer rapidly obtain large volume highquality data increasingly complex semiconductor advanced development specialty diagnostics launched first fdacleared assay risk assessment clinical management preeclampsia firstofakind diagnostic received significant attention adoption significantly raised standard care pregnant woman helping physician better manage care predicting risk condition life science solution introduced gibco ct detachable dynabeads next generation dynabeads platform accelerate manufacturing lifechanging cell therapy continued great innovation momentum fourth quarter electron microscopy launched thermo scientific meridian ex system precise defect localization advanced logic semiconductor low laboratory product launched thermo scientific aquanex ultrapure water purification system reliable water purity operational enhancement laboratory another spectacular year innovation exciting pipeline future also continued strengthen industryleading commercial engine trusted partner status earned customer included opening stateoftheart customer center excellence milan showcase industryleading product service expertise fourth quarter strengthened position advanced material opening customer experience center battery manufacturing seoul accelerate development next generation environmentally friendly energy solution also made significant advancement partnership collaboration customer throughout year building longstanding relationship borenger ingelheim great example fourth quarter exciting opportunity develop genomic testingbased companion diagnostic nonsmall cell lung cancer patient japan united state lung cancer leading cancer death let turn ppi business system mission driven culture continued enable successful execution year ppi engages empowers colleague find better way every day helping u drive share gain improve quality productivity customer allegiance proud way team leveraged ppi step agile way navigate dynamic environment last year driving higher commercial intensity actively managing cost base optimizing sourcing also leveraging generative ai part ppi business system toolkit increase productivity optimize commercial effectiveness improve customer experience quick recap capital deployment last year continued successfully execute disciplined capital deployment strategy combination strategic returning capital shareholder term completed acquisition binding site protein diagnostics business enhances specialty diagnostics offering advancing diagnosis management patient multiple myeloma immune disorder integration gone smoothly business performing extremely well tracking ahead deal model look future protein diagnostics business launch exent instrument solution represents significant breakthrough given enhanced sensitivity specificity ease use compared conventional method great complement freelite assay strong interest medical community due positive impact diagnosing multiple myeloma patient third quarter added corevitas leading provider regulatory grade realworld evidence approved medicine therapy corevitas integrated clinical research business customer seeing benefit additional capability business great start performing well fourth quarter announced intent acquire olink provider advanced proteomic solution help researcher gain understanding disease protein level rapidly efficiently reminder olink technology compliment leading mass spectrometry life science platform uniquely positioned rapidly bring technology customer transaction track completed mid subject customary closing addition including regulatory approval also returned billion capital shareholder stock buyback dividend let give brief update corporate social responsibility initiative missiondriven company help make world better place enabling important work customer also positive impact supporting community good steward planet proud action took regard building environmental sustainability initiative continue accelerate transition renewable energy onsite solar project power purchase agreement around world progress help u achieve recently established target utilizing renewable electricity globally advance global health equity fourth quarter announced partnership project hope improve wellbeing treatment outcome young people living hiv nigeria country secondlargest hiv epidemic worldwide throughout year thermo fisher scientific recognized industry leadership inclusive culture colleague missiondriven career list recognition included fortune list world admired company well fortune inaugural list innovative company newsweek named u one america responsible company forbes included u list world top company woman named u one best employer veteran reflect year proud team accomplished thanks incredible colleague successfully navigated environment continued build bright future company excited beyond let turn guidance stephen outline assumption factor revenue earnings guidance let quickly cover highlight initiating revenue guidance range billion billion adjusted eps guidance range per share outlook reflects continuation u demonstrating incredibly strong commercial execution operational discipline enabling success customer opportunity connect many customer january understand mind based longstanding relationship terrific access senior executive team customer conversation clear customer value partnership see u essential enabling success enthusiastic future progress pipeline treat disease also great enthusiasm material science customer important advance made field create strong longterm demand capability enable customer scientific breakthrough continue incredibly wellpositioned enable customer make world healthier cleaner safer summarize key takeaway proven growth strategy continues drive significant share gain continue elevate trusted partner status deepen relationship many customer last year combination power ppi business system delivered differentiated performance quarter full year helping u effectively navigate challenging macroeconomic environment wellpositioned deliver differentiated shortterm performance strengthen longterm competitive position turn call cfo stephen williamson stephenstephen williamson senior vice president chief financial officer thanks marc good morning everyone saw press release executed really well q market condition played largely expected quarter great execution delivered core organic revenue growth prior guide term adjusted eps beat prior guide included offsetting additional fx headwind really strong operational execution quarter also capped year strong free cash flow delivering billion throughout year navigated changing macro environment effectively proven growth strategy ppi business system enabled u deliver differentiated experience customer differentiated financial result shareholder continuing invest business advance strategic position world leader serving science let provide additional detail performance beginning earnings result delivered adjusted eps q full year gaap eps quarter full year top line reported revenue lower year year q component q reported revenue change included lower organic revenue contribution acquisition tail end foreign exchange q core organic revenue decreased fullyear reported organic revenue decreased core organic revenue growth year delivered billion pandemicrelated revenue million testing billion vaccine therapy revenue turning organic revenue performance geography organic growth rate region skewed pandemicrelated revenue quarter current year prior year q north america declined low double digit europe declined low single digit asia pacific grew low single digit china declining midsingle digit full year north america declined high single digit europe declined low single digit asiapacific declined low single digit china declining high single digit respect operational performance delivered billion adjusted operating income quarter adjusted operating margin basis point higher q last year quarter continued deliver exceptionally strong productivity achieved good price realization partially offset lower pandemicrelated revenue strategic investment fx strength productivity reflects impact ppi business system enabling u manage cost base appropriately given macro condition full year adjusted operating income decreased adjusted operating margin line prior guide total company adjusted gross margin quarter came basis point higher q last year change gross margin due driver adjusted operating margin full year adjusted gross margin moving detail pl adjusted sga quarter revenue improvement basis point q last year full year adjusted sga revenue improvement basis point compared total rd expense million q full year rd expense billion reflecting ongoing investment highimpact innovation rd percent manufacturing revenue looking result line q net interest expense million million lower q net interest expense full year million increase million year year adjusted income expense net expense quarter million million higher q primarily due change nonoperating fx full year adjusted income expense net expense million compared net income million adjusted tax rate quarter full year basis point lower q last year basis point lower full year reflecting result tax planning activity average diluted share million q approximately million lower year year driven share repurchase net option shortly yearend january repurchased billion share turning cash flow balance sheet fullyear cash flow operation billion mentioned earlier free cash flow billion investing billion net capital expenditure returned million capital shareholder dividend q million full year year invested billion completed acquisition committed billion acquisition olink expect close mid ended quarter billion cash billion total debt leverage ratio end quarter time gross debt adjusted ebitda time net debt basis concluding comment total company performance adjusted roic reflecting strong return investment generating across company provide color performance four business segment let start couple framing comment scale margin profile pandemicrelated revenue varies segment revenue higher prior year skew reported segment growth rate margin continue execute strong pricing realization across segment address inflation moving segment detail starting life science solution q reported revenue segment declined organic revenue lower prioryear quarter driven runoff pandemicrelated revenue segment well lower level activity bioproduction business versus yearago quarter full year reported organic revenue lower q adjusted operating income life science solution decreased adjusted operating margin basis point versus prioryear quarter quarter delivered exceptionally strong productivity partially offset unfavorable volume pullthrough team done excellent job appropriately managing cost base dealing unwind pandemic full year adjusted operating income declined adjusted operating margin analytical instrument segment reported revenue increased q organic growth also strong growth segment quarter led electron microscopy business full year reported organic revenue higher segment q adjusted operating income increased adjusted operating margin basis point year year quarter delivered strong productivity volume pullthrough partially offset fx strategic investment full year adjusted operating income increased adjusted operating margin increase basis point versus prior year turning specialty diagnostics q reported revenue declined organic revenue lower prior year quarter q continued see strong underlying growth core led transplant diagnostics microbiology immunodiagnostics business offset lower pandemicrelated revenue versus yearago quarter full year reported revenue declined organic revenue q adjusted operating income specialty diagnostics increased quarter adjusted operating margin basis point higher q q delivered strong productivity favorable business mix partially offset lower impact lower covid testing volume strategic investment full year adjusted operating income higher adjusted operating margin increase basis point versus finally laboratory product biopharma service segment q reported revenue decreased organic revenue lower prioryear quarter driven runoff vaccine therapy revenue phasing revenue pharma service business within expected full year reported organic revenue higher segment q adjusted operating income declined adjusted operating margin basis point lower q quarter delivered strong productivity offset unfavorable volume mix full year adjusted operating income higher prior year adjusted operating margin increase basis point versus let turn guidance marc outlined initiating revenue guidance range billion billion adjusted eps guidance range guidance assumes core organic revenue growth range minus positive view expected market condition changed significantly initial framing year shared last earnings call assuming market decline low single digit year growth strategy ppi business system execution enable u continue take share year current estimate pandemicrelated revenue million testing revenue million million vaccine therapiesrelated revenue total represents yearoveryear headwind billion billion revenue expected increase revenue million year year combination six month olink revenue inorganic portion corevitas revenue current rate expect fx neutral year year revenue adjusted eps phasing standpoint fx expected slight headwind q offsetting tailwind second half turning margin guidance range assumes adjusted operating income margin continue aggressively manage cost base reflected margin outlook term range margin driven revenue range provided continue use ppi business system manage cost carefully also continue make right longterm investment enable u advance industry leadership strong underlying productivity cost control including carryover benefit cost action put place last year expected largely offset runoff remaining pandemicrelated revenue inflation normalization incentive compensation across company appropriately invest colleague line expect approximately million net interest expense expect adjusted income expense net close zero assume adjusted income tax rate tax line factor million profit elimination related minority interest expecting billion billion net capital expenditure assuming free cash flow range billion billion year term capital deployment guidance assumes billion share buyback mentioned earlier already completed january estimate fullyear average diluted share count approximately million share assuming return approximately million capital shareholder year dividend assuming closed acquisition olink midyear finally wanted touch quarterly phasing year thing consider first term organic revenue growth expect q better sequentially q point improve quarter year implied core organic revenue growth q similar q core organic revenue growth also expected improve quarter year leading moderate growth second half year margin standpoint expect q increase quarter throughout year level expect q adjusted earnings per share approximately full year conclusion navigated challenging environment successfully stepped customer delivered differentiated financial performance shareholder continue manage company agility really wellpositioned year ahead look forward updating progress go year turn call back rafrafael tejada vice president investor relation thank stephen operator ready qa portion call question answer operatorthank operator instruction first question today come line jack meehan nephron research please go ahead line openjack meehan nephron research analyst thank good morning marc look business look business think question start see recovery could talk part think could grow le market mean term revenue earningsmarc casper chairman president chief executive officer yes jack think last year heard u say delivering differentiated shortterm performance strengthen company long term kind simultaneously opportunity look obviously first nine month others done looked company preannounced reported far really strong year term delivering abovemarket growth mean share gain right share gain actually broadbased term performance look thing like analytical instrument strong clinical research pharma service business well absence implying anything others strong year relative challenged set market condition think future wellpositioned business continue share gain momentum made assumption year pretty much said back late october assuming full year going pretty similar mirror image meaning start lap comp year unfolds wind market slightly low single digit u performing better level excited year unfolds position deliver differentiated performance certainly going capitalize improvement market hold high standard good look likejack meehan nephron research analyst ok specific business talk example script think talked transitioning capacity new therapy like potential recovery like talk expect phasing patheon bioprocessing businessmarc casper chairman president chief executive officer yes think year basically use range outcome business term perform believe second half year based lapping comp well expecting market condition improve slightly year unfolds help demand industry u would think business aggregate way manage company thank jackjack meehan nephron research analyst thank youoperatorthe next question today come line dan aria stifel please go ahead line opendan aria stifel financial corp analyst good morning guy thanks question marc obviously lot discussion destocking across industry maybe add color think process maybe draw distinction u inventory workdown taking place bioprocess side specifically versus routine consumables split way drawdowns kind happening similar pace ending similar time think sort keep two bucket separately think differentlymarc casper chairman president chief executive officer yes dan guess let start sort bioproduction think essence question maybe step one level term bioproduction incredibly good longterm market historically incredibly good market sort taboo name day right term bioproduction caused lot volatility certainly industry u couple fact little bit revenue bestinclass bioprocessing product incredible global footprint leading position cell culture medium singleuse technology increasingly important purification business grow share position think fourth quarter see sequential pickup order q versus q underlying activity still muted right market see inflection expecting one see one fourth quarter view normalize year unfolds said investor conference earlier year one going get rewarded calling moment inflection happens play course year longterm fundamental strong think business general coming year think thing exciting trusted partner status earned customer many many year room decisionmakers understand mind incredibly wellpositioned think midterm outlook clinical research pharma service bioproduction channel business incredibly wellpositioned right term part helping customer bring breakthrough pipeline part helping navigate whatever environment hopefully helpful maybe last comment would make one takeaway many many customer interaction first month year biotech community mean biotech call smaller company capital marketdependent company pharmaceutical segment much positive right seeing green shoot love activity happening end year get investor excited new company formation new round capital early take time certainly optimistic seen last five quarter term tone view think bodes well coming year thank youdan aria stifel financial corp analyst ok encouraging maybe followup ai piece consistently solid growth curious still carrying backlog microscopy maybe talk little bit lead time order conversion year assumption might get extended move year think maybe stable relative today thanksmarc casper chairman president chief executive officer yes think performance analytical instrument business doubledigit growth full year awesome really tremendous year across three business backlog carried beginning thing largely cleared first half normal lead time normal shipping time really six month term already kind normal spot yeah repeat unwind pandemic impact supply chain business positioned good year high demand breakthrough technology whether electron microscopy semiconductor material science life science astral right chroma mass spec incredible demand technology excited upcoming year future businessoperatorthank next question today come line derik de bruin bank america please go ahead line openderik de bruin bank america merrill lynch analyst hi good morning everyonemarc casper chairman president chief executive officer good morning derikderik de bruin bank america merrill lynch analyst marc sort curious last quarter talking core growth sort looking initial framework heard correctly plus minus seem like q got lot worse anything sort changed conservative ppd business conservative tough comp sort curious embedded like conservative outlookmarc casper chairman president chief executive officer stephen stephen williamson senior vice president chief financial officer yes let provide context guidance kind step back hopefully help frame question provided early framing last call insight q played completed detailed planning work business process view market outlook changed significant guidance significantly different initial framing provided includes latest view fx rate expected mix revenue cost currency increased revenue initial framing impact operating income reduces margin basis point initial framing operational standpoint think item note changed past three month discrete item pharma service business transitioning sterile fill finish capacity covid vaccine support glp support would expecting recognize upfront fee q accounting finalized expect recognize benefit line production actually start shifted approximately q impact term reported core growth one comment guidance thought best provide range point estimate thing helpful investor range outcome year range encapsulate every possible scenario year capture reasonably likely scenario year play see today range billion revenue adjusted eps think appropriate given scale company hopefully kind tee kind framing guidederik de bruin bank america merrill lynch analyst ok little bit sort think segment margin go mean sort looking mean seen really good progress l may seem good progress margin expansion margin across sort thinking think lp given margin range seeing full year sort sustainable fall back next year trying figure margin hit given relative expectation werestephen williamson senior vice president chief financial officer term margin profile finished year exactly guided full year margin profile company think change term q versus segment think everyone quite understood phasing revenue within lab product biopharma service see precall note think little bit different term expectation expectation internally q played would expected margin going forward think margin profile today calling significant difference margin profile going forward next year think landing point margin segment probably good starting point think year aheadderik de bruin bank america merrill lynch analyst ok thank youoperatorthe next question today come line doug schenkel wolfe research please go ahead line opendoug schenkel wolfe research analyst right good morning everybody thanks taking questionsmarc casper chairman president chief executive officer good morning doug welcome backdoug schenkel wolfe research analyst thanks great back working great focus like team want start highlevel lrp question followup really clarification lp lrp marc consistent saying thermo built grow two three point better peer group long term said talk growth recently last year analyst day sure two three point changed flip calendar fair say growth rate maybe little bit high even normalized environment want give opportunity maybe adjust kind flip calendar look ahead top line done fantastic job always leaning operation challenging period never let good crisis go waste guidance suggests least surface may investing near term think return normal wondering think could get outsized incremental margin flowthrough business business normalizes let leave ask quick followup lp secondmarc casper chairman president chief executive officer sure doug thanks question term longrange outlook right raised outlook late moment remember exactly moment growing right growing extraordinary organic rate wanted give investor longterm view market position market right term ability gain share three point think two three use three simplicity three point faster market kind standard hold delivering growing share really long many many many year nothing changed term market growth market extraordinary set said going underlying market growth higher change actually larger exposure pharma biotech built business capability look future think going driver long term industry feel incredibly confident growth industry wellpositioned grow simplicity three point faster get question lot obviously period delivered core growth long way view market declining low single digit last year reflects least share gain component look future continue remain confident longterm health industry really interesting discussion investor basically went logic saying bullish life science tool diagnostics pharma service probably longterm growth bearish life science tool diagnostics pharma service probably industry growth incredibly bearish world actually get le industry growth long term segment really gdpplustype business term market serve hopefully give least sense think appreciate offer change outlook could confident future industry competitive position term line highlevel concept believe see volume grow normalized rate see strong flowthrough margin part going margin year reset incentive compensation colleague back normalized level year math level headwind embedded easier number nothing different expected october part see much margin stepup one would expect havedoug schenkel wolfe research analyst ok going leave lp question another day guess part question margin marc obviously got pay people got reset thing period growing much thermo historically played offense others played defense certain extent wondering actually pulling forward investment early year could next several quarter lead even betterthanexpected margin flowthrough company return normalized periodstephen williamson senior vice president chief financial officer yes doug think example gave glp contract basically standing facility customer getting paid fee get recognize fee production volume incurring substantial cost interim create good accretive growth going forward one good example continuing invest innovation across company lessening drive really drive great longterm growth appropriately managing cost topline environment making sure actually putting right investment place make sure top line environment stay outlook stay good much articulateddoug schenkel wolfe research analyst ok leave thanks muchstephen williamson senior vice president chief financial officer thanksoperatorthe next question today come line vijay kumar evercore isi please go ahead line openvijay kumar evercore isi analyst hi marc good morning thanks taking question first one marc look annual guidance core flattish midpoint excluding vaccine headwind three point pretty solid guide three thing come china cro business analytical tech remind u china ppd fiscal guide assuming three piece china cro analytical tech thank youmarc casper chairman president chief executive officer vijay thanks question think performance business certainly last year certainly look future last year spectacular performance clinical research business really team unbelievably good job term result think way probably undersold detail number much actually going many different thing communicating think clinical research little two year acquisition phenomenal acquisition customer love business performing well colleague great job big success business pandemic played largest role supporting clinical trial vaccine time delivered far fastest call underlying growth excluding covid activity crushed mean year rolloff given transparency big chunk vaccine revenue fine generated really substantial comparison cool like good challenge term great performance would expect business growth would much moderate year based comparison future meaning looking beyond really strong business longterm high singledigit growth business plus synergy driving feel really great quick comment china unrelated clinical research sort element question china market condition challenged first quarter really strong lot stimulus good thing china effectively calling meaningful improvement china year rather lap comparison year unfolds becomes little bit le headwind know point chinese government create mechanism stimulus whether direct confidence whatever know happen point improve market condition need high bullish long term better china experiencing currently take time get therevijay kumar evercore isi analyst great thanks marc stephen one quick one q think operating margin slightly think eps around ish outsized impact incentive comp reset want understand q margin cadencestephen williamson senior vice president chief financial officer yeah think margin q definitely element look year year kind sequentially well think year year obviously significant drag lower pandemic revenue reset incentive comp basis point total basis point contribution core business despite lower dollar revenue key driver impact cost action taken past year give way frame margin q yes margin profile grows quarter revenue dollar grow year term profile year ahead thanks vijayvijay kumar evercore isi analyst helpful thank guysrafael tejada vice president investor relation operator time one questionoperatorthank final question today come line tejas savant morgan stanley please go ahead line opentejas savant morgan stanley analyst hey guy good morning thanks time marc followup china commentary term longterm opportunity talked past important market growing higher end outlook company recently thawing relation last month think kind alluded well highlevel government engagement little ago got word biosecure act legislation help u think sort entail perhaps opportunity front footed gain share nearterm service side versus kind longterm risk potential blowback chinese side term yous mncs operating market would super helpful thank youmarc casper chairman president chief executive officer sure thanks question term china market year set capability built long period time helped chinese society right created american job part better food supply addressing air pollution helping produce medicine local population great reputation honor chair youschina business council last couple year interacting yous administration chinese government clear shortterm gdp environment challenged china need industry thermo fisher long term good solid growth market certainly one fastergrowing geography long term term relation country yes agree sentiment thawing term potential legislation thousand bill written happen something sort matures process hard really know whether come pas exact implication quick read working particular one really basically opportunity nonchinese company stronger position serving federal governmentrelated entity sort essence obviously nonchinese company would wellpositioned support yous government thank question let quick wrap call thanks everyone participating call today entered year strong momentum great position deliver excellent year always thank support thermo fisher scientific look forward updating year progress thanks everyoneoperatoroperator signoff duration minutescall participantsrafael tejada vice president investor relationsmarc casper chairman president chief executive officerstephen williamson senior vice president chief financial officerjack meehan nephron research analystdan aria stifel financial corp analystderik de bruin bank america merrill lynch analystdoug schenkel wolfe research analystvijay kumar evercore isi analysttejas savant morgan stanley analyst tmo analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends thermo fisher scientific motley fool disclosure policy